Quest Diagnostics Reports Strong Q2 Results and Raises Full-Year Outlook
Quest Diagnostics (NYSE:DGX) reported strong financial results for its second quarter of fiscal year 2026, with revenue rising to $3.04 billion — a 10.2% increase from the prior year. Adjusted earnings per share reached $3.12, driven by broad demand across physician, hospital, and consumer channels as well as contributions from partnerships with Corewell Health and Fresenius Medical Care. The company raised its full-year revenue guidance to between $11.95 billion and $12.05 billion — a projected growth of 8.3% to 9.2%. Adjusted EPS is now expected in the range of $11.05 to $11.25, reflecting strong performance across key business segments including hospital testing, advanced diagnostics, and consumer health. Quest also highlighted continued investments in automation and AI initiatives aimed at improving efficiency and reducing costs despite anticipated higher spending in the second half due to Project Nova expenses and rising fuel costs.
Topics: adjusted_eps financial_results outlook_update revenue_growth